# Jifeng Feng

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jifeng-feng/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,551 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 64 |
| i10-index | 256 |
| Last Known Institution | Guangxi Zhuang Autonomous Region Health and Family Planning |
| OpenAlex ID | https://openalex.org/A5100728900 |
| ORCID iD | https://orcid.org/0000-0002-7979-2391 |
| Works | 498 |

## Researcher papers

Showing 12 of 18.

- [Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study](https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial](https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for-the-treatment/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)](https://scholariq.org/papers/efficacy-safety-and-correlative-biomarkers-of-toripalimab-in-previously-treated/)
- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)

## Researcher university

- [Guangxi Zhuang Autonomous Region Health and Family Planning](https://scholariq.org/institutions/guangxi-zhuang-autonomous-region-health-and-family-planning/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.